The IRESSA Novel Head and Neck Chemotherapy Evaluation Study

AstraZeneca64 enrolled

Overview

The purpose of this study is to compare the objectie tumour response rate between the cisplatin/5FU and cisplatin/5FU plus ZD1839 combination

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Squamous Cell Cancer Cancer of Head and Neck

Interventions

gefitinibDRUG

cisplatinDRUG

5-flourouracilDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Provision of written informed consent * Patients with histologically proven primary SCCHN * Aged 18 or over Exclusion Criteria: * Patients eligible for surgery with curative intent * Other co-existing malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ * Exclude UCNT

Locations (1)

Research Site

London, United Kingdom

Outcomes

Primary Outcomes

To compare the objective tumour response rate between cisplatin/5FU and cisplatin/5FU and ZD1839 combination in these patients

Secondary Outcomes

To compare safety and tolerability in these patients

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.